Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)

NCT00261378 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT00261378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00261378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)
Lead sponsor
Boston Scientific Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
January 31, 2008
Enrollment
212 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

primary liver cancer